Chlorogenic acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Chlorogenic acid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Chlorogenic acid can convert its Small molecule drug profile and Akt x DNMT1 x LAG3 x SLC37A4 x TGF-β1 x bFGF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Chlorogenic acid (query alias: Chlorogenic acid) |
|---|---|
| Modality / target | Small molecule drug; Akt x DNMT1 x LAG3 x SLC37A4 x TGF-β1 x bFGF; Akt stimulants, DNMT1 inhibitors, LAG3 inhibitors |
| Highest global status | Phase 2 |
| Originator | Sichuan Jiuzhang Biotechnology Co Ltd |
| Active developers | Sichuan Jiuzhang Biotechnology Co Ltd, Hunan University of Chinese Medicine, Universiti Putra Malaysia |
The MCP disease footprint includes Recurrent Glioma, Advanced Lung Adenocarcinoma, Advanced Lung Small Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| IRCT20230727058938N1 | Phase 3 | Recruiting | 144 | Primary endpoint not disclosed in English source |
| RBR-835555x | Not Applicable | Not yet recruiting | Not disclosed | Primary endpoint not disclosed in English source |
| IRCT20200511047401N2 | Not Applicable | Complete | 40 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
657O - A randomized, controlled, multicenter, phase II/III clinical study to evaluate the safety and efficacy of chlorogenic acid for injection in the treatment of recurrent grade IV glioblastoma (GBM)
Phase 2/3; n=200; evaluation: Positive. Reported fields: mOS = 263.0 Day ; mOS = 249.0 Day
Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial.
Phase 2/3; n=26; evaluation: Not stated in English source. Reported fields: Body weight = -3.69 kg ; Body weight = -0.7 kg
Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance
Phase 2; n=30; evaluation: Not stated in English source. Reported fields: FBG(Median) = 5.8 mmol/L ; FBG(Median) = 5.5 mmol/L
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Chlorogenic acid addresses Recurrent Glioma, Advanced Lung Adenocarcinoma, Advanced Lung Small Cell Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 24 matched transaction record(s) under the scope “target-level comparable: Akt x DNMT1 x LAG3 x SLC37A4 x TGF-β1 x bFGF.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Akt x DNMT1 x LAG3 x SLC37A4 x TGF-β1 x bFGF records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties | Approved | Financial terms not disclosed |
| 2025-11-12 | Fangda Assisted Laekna in Entering into an Exclusive Licensing Agreement with Qilu Pharma for LAE002 (AFURESERTIB) in China | Phase 3 | US$287.3M stated total |
| 2025-03-05 | Jazz Pharmaceuticals Completes Acquisition of Chimerix | NDA/BLA | US$935.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation and purification method of high-purity chlorogenic acid”. The milestone feed surfaced a patent-application signal described as “In-situ adhesion gel filler with biofilm attacking and dual osteogenesis promoting functions as well as preparation method and application of in-situ adhesion gel filler”. The milestone feed surfaced a patent-application signal described as “Cellular-imitated nano preparation for treating acute respiratory distress syndrome”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
